KYORIN Pharmaceutical Co.,Ltd. · TSE:4569

KYORIN Pharmaceutical Co.,Ltd — Q3 FY2021 Earnings Presentation

21 slides from KYORIN Pharmaceutical Co.,Ltd's earnings presentation, Feb 4, 2022

  1. Slide 1: Q3 FY 2021 Financial Results

    Q3 FY 2021 Financial Results Ended Dec 31, 2021 February 4 , 2022 KYORIN Holdings, Inc. President Yutaka Ogihara

  2. Slide 2: Agenda

    ➢ Outline of Consolidated Financial Results ➢ Consolidated Financial Forecast ➢ Status of R&D Pipeline ➢ Renovation of the Group Structure 1

  3. Slide 3: Outline of Consolidated Financial Results

    Outline of Consolidated Financial Results 2

  4. Slide 4: Segment Sales and Breakdown of Gain and Loss

    Segment Sales and Breakdown of Gain and Loss Change Progress to Full (Units: ¥billion) Dec /20 Dec /21 Change Term Forecast (%) (%) Sales 75.0 77.7 n/a n/a 75.7 New ethical drugs, etc. 51.7 52.4 n/a n/a 76.3 (Japan) New ethical drugs(Overseas) 0.8 0.5 n/a n/a 61.7 Generic drugs 22.5 24.9 n/a n/a 75.

  5. Slide 5: Highlights of Business Performance: Net sales

    Highlights of Business Performance : Net sales (Units: ¥billion) 80 77.7 75.0 70 22.5 24.9 New ethical drugs, etc.(Japan) 60 Increased 0.8 0.5 ・New drugs (Beova,Desalex,Lasvic) grew 50 ・Sales of long-listed products (Pentasa, Mucodyne etc.) increased 40 New ethical drugs (Overseas) Decreased 30 51.7

  6. Slide 6: Main Product Sales Update

    Main Product Sales Update (Units:¥billion) Change FY2021 Progress to Dec /20 Dec /21 Change Full Term (%) (Forecast) Forecast(%) Flutiform (Combination drug for asthma treatment) 10.2 9.8 -0.4 -4.6 13.9 70.0 Desalex (Antiallergic Agent) 3.1 4.3 +1.2 +38.3 7.2 59.8 Beova (β3 adrenergic receptor agoni

  7. Slide 7: Highlights of Business Performance: Operating Income

    Highlights of Business Performance : Operating Income (Units:¥billion) 80.0 Net sales increased 70.0 Cost of sales ratio increased Cost of Cost of <Reason of decrease> 60.0 sales ratio sales ratio ⚫ Sales of new drugs increased 53.4% <Reasons of increase> 48.2% ⚫ Impact of NHI drug price revision Co

  8. Slide 8: Consolidated Financial Forecast

    Consolidated Financial Forecast 7

  9. Slide 9: Consolidated Financial Forecast in FY2021

    Consolidated Financial Forecast in FY2021 FY2021 Y/Y FY2020 (Units:¥billion) (Forecast) Change Change(%) Net 102.9 102.6 n/a n/a sales New ethical drugs, etc.(Japan) 69.7 68.6 n/a n/a New ethical drugs (Overseas) 1.0 0.8 n/a n/a Generic drugs 32.2 33.1 n/a n/a Cost of Sales 51.3 ー ー ー SG&A 45.8 ー ー

  10. Slide 10: Impact of fire at West Japan Distribution Center

    Impact of fire at West Japan Distribution Center Situation of Fire of West Japan Delivery Center of KYORIN Pharmaceutical Date and time of Fire : AM8:50, November 29, 2021 (Extinguished PM5:00, December 4) Place : Hitachi Transport System West Japan Co., Ltd. Maishima office (Osaka-City) Damage situ

  11. Slide 11: Status of R&D Pipeline

    _Kyorin @ Status of R&D Pipeline

  12. Slide 12: Drug R&D Pipeline: Progress

    Drug R&D Pipeline: Progress Progress in FY21 ※Change from the previous presentation(Nov.8,21) Approval/ Development code PhⅠ PhⅡ PhⅢ Application Launch KRP-R120 Completed Respiratory ※ Ryfnua Tablets MSD approved 45mg (Jan,2022) Infections KRP-A218 (Apr,2021) Launched KRP-116D (Apr,2021) Urology ※ A

  13. Slide 13: FPR2 agonist program

    FPR2 agonist program Out-licensee Bristol-Myers Squibb(BMS) Progress ⚫ Concluded a license agreement related to out-licensing (Dec, 2015) ⚫ BMS announces that it is conducting a Ph1 study in the cardiovascular area (Jan, 2018) ⚫ KYORIN and BMS have given presentations at American Chemical Society Na

  14. Slide 14: LYFNUA Tablets 45mg

    LYFNUA® Tablets 45mg, selective P2X3 receptor antagonist for the treatment of chronic cough (Generic name: gefapixant citrate) ◼ Concluded an agreement for exclusive distribution rights in Japan (Apr, 2021) ◼ MSD received manufacturing and marketing approval (Jan, 2022) Indication Refractory chronic

  15. Slide 15: LAGEVRIO Capsules 200mg

    LAGEVRIO® Capsules 200 mg, an oral antiviral drug (Generic name: molnupiravir) ◼ MHLW granted a special approval for emergency to LAGEVRIO (Dec, 2021) ◼ KYORIN and MSD concluded a co-promotion agreement (Jan, 2022) ◼ Both companies started co-promotion (Jan 31, 2022) Indication SARS-CoV-2 infection

  16. Slide 16: Renovation of the Group Structure

    Renovation of the Group Structure 15

  17. Slide 17: Background of Renovation of the Group Structure

    Background of Renovation of the Group Structure HOPE 100 Long term vision Mid-term Management Plan Kyorin MIC-09 Stage 1 Stage 2 Stage 3 2005-2009 2010-2015 2016-2019 2020-2023 Unique and integrated Corporate Image healthcare company Company that supports healthy lifestyles centered on drug discover

  18. Slide 18: Outline of the Group Structure Renovation

    Outline of the Group Structure Renovation To become “a globally recognized company by creating innovative new drugs” Strongly promote new drug businesses at the core and develop medical- Business related businesses promotion function Increase management efficiency and providing new value to patients

  19. Slide 19: The Group chart

    The Group chart Merger scheme and date Change Scheme KYORIN Holdings will absorb KYORIN pharmaceutical and change its trade name to KYORIN pharmaceutical Expected Merger Date April 1, 2023 [ Pure Holding Company Structure ] KYORIN Holdings,Inc. Absorption-type merger KYORIN KYORIN KYORIN Rimedio Pha

  20. Slide 20: Disclaimer

    Disclaimer This material contains performance forecasts, goals and plans, and other forward- looking statements related to the Group. These statements are based on the judgment of the Group’s assumptions and outlooks based on the information and forecasts available at the time of preparation of this

  21. Slide 21: Kyorin ©)

    Kyorin ©) Kyorin ©)

KYORIN Holdings — Q3 FY2021 Earnings Presentation on 6ix